Assess whether the primary endpoint will survive FDA scrutiny (d0a854)

SITUATION A safety team sitting on a new disproportionate signal cannot treat a boxed-warning proposal from the review division as incidental context on scientific-advice briefing book. Regulatory-affairs lead must close the primary endpoint will from that extract under Pharma & Life Sciences / CMC and Development Pathways.

DECISION Regulatory-affairs lead in a safety team sitting on a new disproportionate signal must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using scientific-advice briefing book after a boxed-warning proposal from the review division.

HYPOTHESES TO TEST 1. Regulatory-affairs lead can defend Proceed under protocol from scientific-advice briefing book after a boxed-warning proposal from the review division in a Pharma & Life Sciences challenge. 2. Regulatory-affairs lead cannot defend Proceed under protocol from scientific-advice briefing book; Pause the pathway is what the extract actually supports after a boxed-warning proposal from the review division. 3. A boxed-warning proposal from the review division never reached the population in scientific-advice briefing book — reopen intake, do not close the primary endpoint will. 4. Two facts in scientific-advice briefing book after a boxed-warning proposal from the review division conflict for regulatory-affairs lead; hold this CMC and Development Pathways file.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in a safety team sitting on a new disproportionate signal. 2. Trace CMC, labeling, or pharmacovigilance facts in scientific-advice briefing book after a boxed-warning proposal from the review division. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read scientific-advice briefing book against a boxed-warning proposal from the review division and write the one fact that would move the primary endpoint will for regulatory-affairs lead.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (scientific-advice briefing book after a boxed-warning proposal from the review division). If scientific-advice briefing book cannot force a Pharma & Life Sciences label under CMC and Development Pathways, stop. If scientific-advice briefing book after a boxed-warning proposal from the review division cannot support Proceed under protocol versus Pause the pathway on this Pharma & Life Sciences CMC and Development Pathways close, regulatory-affairs lead must state the unresolved clinical or safety evidence requirement explicitly.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on the primary endpoint will, then the evidence in scientific-advice briefing book, then the action for regulatory-affairs lead - Hypothesis scorecard against scientific-advice briefing book: supported / rejected / untestable - What changes the primary endpoint will if a boxed-warning proposal from the review division is later withdrawn - Named option among Proceed under protocol, Pause the pathway, Escalate safety review and the fact that kills the others